Kymera Therapeutics (KYMR) Capital Leases (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Capital Leases data on file, last reported at $1.2 million in Q1 2026.

• Capital Leases for Q1 2026 came in at $1.2 million, down 39.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (down 39.68% YoY), and the FY2025 annual result was $1.5 million, down 34.32% from the prior year.
• Capital Leases eased to $1.2 million in Q1 2026 per KYMR's latest filing, from $1.5 million in the prior quarter.
• Over five years, Capital Leases peaked at $2.2 million in Q4 2024 and troughed at $643000.0 in Q3 2023.
• A 5-year average of $1.3 million and a median of $1.2 million in 2024 frame the typical range for Capital Leases.
• The sharpest annual moves came in 2022 and 2024: Capital Leases slumped 48.78% in 2022, then soared 171.23% in 2024.
• A 5-year view of Capital Leases shows it stood at $1.2 million in 2022, then advanced by 4.41% to $1.3 million in 2023, then jumped by 71.1% to $2.2 million in 2024, then tumbled by 34.32% to $1.5 million in 2025, then slipped by 21.27% to $1.2 million in 2026.
• Business Quant data shows KYMR's Capital Leases at $1.2 million in Q1 2026, $1.5 million in Q4 2025, and $1.8 million in Q3 2025.